Skip to content

Psilocybin and microdosing: all studies

Page 3 of 6: studies 21 to 30 of 55, newest first. Back to the psilocybin and microdosing overview

Research

Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?

International review of neurobiology 2025 Iva Totomanova, Eline Haijen, Petra P M Hurks et al.

Clinical trials using full doses of psychedelics have provided preliminary evidence supporting their safety and efficacy in treating a variety of physical and psychological conditions. Anecdotal reports indicate that even very small amounts of these substances may provide therapeutic benefits, though robust clinical studies are still needed. This chapter reviews the current experimental studies...

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.

Neuropsychiatric Disease and Treatment 2025 Daniel A Kinderlehrer 13 citations

The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the...

Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence

Premier journal of science. December 3, 2024 Kanwal Shabir

Background Anxiety disorders are increasingly prevalent among young adults. Traditional treatment options often fall short, and many patients live with treatment-resistant anxiety. Psilocybin is a psychedelic compound that has gained attention for its therapeutic potential against anxiety when used in microdoses. Objective This review aims to evaluate the emerging evidence on psilocybin...

Salience, sensemaking, and setting in psilocybin microdosing: Methodological lessons and preliminary findings of a mixed method qualitative study

Philosophical Psychology September 26, 2024 Aleš Oblak, Liam Korošec Hudnik, Anja Levačić et al. 1 citation

There are profound methodological challenges facing microdosing research. One way we can address some of these methodological issues is by understanding how psilocybin microdosing fits in the broader existential context of people’s lives. We recruited participants who underwent psilocybin microdosing on their own and consented to being monitored for harm mitigation purposes. We combined...

Less is more? A review of psilocybin microdosing

Journal of Psychopharmacology September 16, 2024 Isabella A Savides, Kim Outhoff 11 citations

Background: The applications of psilocybin, derived from ‘magic mushrooms,’ are vast, including a burgeoning practice known as microdosing, which refers to the administration of sub-hallucinogenic doses of psychedelic substances to obtain benefits without experiencing significant cognitive and perceptual distortion. However, current research is fairly new with several limitations and gaps that...

DOI: 10.1177/02698811241278769 (opens in new tab) Psilocybin Observational study Grey literature Clinical psychology +2

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research

Journal of Psychopharmacology June 14, 2024 Vince Polito, Paul Liknaitzky 16 citations

Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing. We conducted a PubMed search for all studies investigating psychedelic microdosing...

DOI: 10.1177/02698811241254831 (opens in new tab) Psilocybin Hallucinogen Placebo Expectancy theory +2

Psychedelic Microdosing among Young Adults from Southern California

Journal of Psychoactive Drugs February 10, 2024 Alyssa F. Harlow, Peter S. Hendricks, Adam M. Leventhal et al. 6 citations

Despite common depictions in the media, there is little scientific evidence on microdosing psychedelic drugs. We assessed awareness, prevalence, and dosing practices of microdosing psychedelic drugs among young adults 18-22 years old from Southern California (2018-2019). We examined whether sociodemographic factors, personality traits, mental health, or other substance use behaviors were...

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats.

Molecular Psychiatry September 1, 2023 Kat F. Kiilerich, Joe Lorenz, Malthe B. Scharff et al. 48 citations

Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in psychedelic-assisted therapy of several psychiatric disorders. A less explored topic concerns the use of repeated low doses of psychedelics, at a dose that is well below the psychedelic dose used in psychedelic-assisted therapy and often referred to as microdosing. Psilocybin microdose users frequently report...

The risk of chronic psychedelic and MDMA microdosing for valvular heart disease

Journal of Psychopharmacology August 12, 2023 Michael Tagen, Daniel Mantuani, Alex Holstein et al. 39 citations

Psychedelic microdosing is the practice of taking very low doses of psychedelic substances, typically over a longer period of time. The long-term safety of chronic microdosing is relatively uncharacterized, but valvular heart disease (VHD) has been proposed as a potential risk due to activation of the serotonin 5-HT 2B receptor. However, this risk has not yet been comprehensively assessed. This...

Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.

BMC Psychiatry March 14, 2023 Rebecca S Ryan, Alex Copello, Andrew P Fox 12 citations

Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential...